Innovative discovery and mechanistic validation of HyT-PD ligands for selective CDK9-targeted protein degradation.
作者信息
Zhai Yizhan, Cai Jianfeng
机构信息
Department of Chemistry, University of South Florida, Tampa, FL 33620, United States.
出版信息
Acta Pharm Sin B. 2025 May;15(5):2808-2809. doi: 10.1016/j.apsb.2025.04.023. Epub 2025 May 14.
Abstract
摘要
相似文献
1
Innovative discovery and mechanistic validation of HyT-PD ligands for selective CDK9-targeted protein degradation.
Acta Pharm Sin B. 2025 May;15(5):2808-2809. doi: 10.1016/j.apsb.2025.04.023. Epub 2025 May 14.
2
First ATG101-recruiting small molecule degrader for selective CDK9 degradation autophagy-lysosome pathway.
Acta Pharm Sin B. 2025 May;15(5):2612-2624. doi: 10.1016/j.apsb.2025.03.047. Epub 2025 Apr 4.
3
Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex.
Chem Biodivers. 2023 Aug;20(8):e202300769. doi: 10.1002/cbdv.202300769. Epub 2023 Jul 13.
4
Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein.
Acta Pharm Sin B. 2025 Apr;15(4):2170-2196. doi: 10.1016/j.apsb.2025.02.033. Epub 2025 Mar 3.
5
Discovery of small molecules for autophagy-lysosome degradation of immune checkpoint proteins.
Eur J Med Chem. 2024 Dec 15;280:116958. doi: 10.1016/j.ejmech.2024.116958. Epub 2024 Oct 16.
6
Discovery of a Potent, selective and orally bioavailable CDK9 degrader for targeting transcription regulation in Triple-Negative breast cancer.
Bioorg Chem. 2024 Dec;153:107876. doi: 10.1016/j.bioorg.2024.107876. Epub 2024 Oct 9.
7
Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.
J Med Chem. 2023 Sep 28;66(18):12877-12893. doi: 10.1021/acs.jmedchem.3c00828. Epub 2023 Sep 6.
8
Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
Expert Opin Drug Discov. 2024 Jul;19(7):799-813. doi: 10.1080/17460441.2024.2360416. Epub 2024 Jun 2.
9
Hydrophobic tag-based protein degradation: Development, opportunity and challenge.
Eur J Med Chem. 2023 Nov 15;260:115741. doi: 10.1016/j.ejmech.2023.115741. Epub 2023 Aug 19.
10
Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
J Med Chem. 2021 Oct 14;64(19):14822-14847. doi: 10.1021/acs.jmedchem.1c01350. Epub 2021 Sep 20.
本文引用的文献
1
Targeted protein degradation: advances in drug discovery and clinical practice.
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
2
Targeted protein degradation: from mechanisms to clinic.
Nat Rev Mol Cell Biol. 2024 Sep;25(9):740-757. doi: 10.1038/s41580-024-00729-9. Epub 2024 Apr 29.
3
Targeting the undruggables-the power of protein degraders.
Sci Bull (Beijing). 2024 Jun 15;69(11):1776-1797. doi: 10.1016/j.scib.2024.03.056. Epub 2024 Mar 29.
4
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.
J Med Chem. 2024 Apr 11;67(7):5185-5215. doi: 10.1021/acs.jmedchem.4c00312. Epub 2024 Apr 2.
5
Hydrophobic tag-based protein degradation: Development, opportunity and challenge.
Eur J Med Chem. 2023 Nov 15;260:115741. doi: 10.1016/j.ejmech.2023.115741. Epub 2023 Aug 19.
6
Targeted protein degradation: mechanisms, strategies and application.
Signal Transduct Target Ther. 2022 Apr 4;7(1):113. doi: 10.1038/s41392-022-00966-4.
7
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
J Med Chem. 2020 Nov 25;63(22):13228-13257. doi: 10.1021/acs.jmedchem.0c00744. Epub 2020 Sep 17.
8
Lysosome biology in autophagy.
Cell Discov. 2020 Feb 11;6:6. doi: 10.1038/s41421-020-0141-7. eCollection 2020.
Zotero 插件